Epigenomics AGFRA:ECX 13 EV-to-FCF is -22.01 as of Jul. 01, 2026. GuruFocus rates FRA:ECX with a GF Score™ of 13/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, Epigenomics AG ranks worse than 1030926.8% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Epigenomics AG's Enterprise Value is €11.73 Mil.
Epigenomics AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.53 Mil. Therefore, Epigenomics AG's EV-to-FCF for today is -22.01.
The historical rank and industry rank for Epigenomics AG's EV-to-FCF or its related term are showing as below:
FRA:ECX'
s EV-to-FCF Range Over the Past 10 Years
Min: -22.88 Med: -1.94 Max: 4.63
Current: -22.01
During the past 13 years, the highest EV-to-FCF of Epigenomics AG was 4.63. The lowest was -22.88. And the median was -1.94.
FRA:ECX's EV-to-FCF is ranked worse than 100% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.51
vs FRA:ECX: -22.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Epigenomics AG's PE Ratio (TTM) for today is calculated as:
Epigenomics AG's share price for today is €0.87.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epigenomics AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.358.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Epigenomics AG EV-to-FCF Related Terms
Epigenomics AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Epigenomics AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's EV-to-FCF falls into.
Epigenomics AG's current Enterprise Value is €11.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Epigenomics AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigenomics AG (FRA:ECX) has a EV-to-FCF of -22.01 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Epigenomics AG and its competitors. According to the industry distribution chart, Epigenomics AG ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry.
Is Epigenomics AG's EV-to-FCF too high?
Epigenomics AG's current EV-to-FCF is -22.01. Based on the distribution chart, Epigenomics AG ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Epigenomics AG has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #999999 out of 97 companies for EV-to-FCF. This places Epigenomics AG in the lower half of its industry. The industry median EV-to-FCF is 22.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.51, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Epigenomics AG and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current EV-to-FCF is -22.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.87 — trading 866.7% above its estimated fair value. The current EV-to-FCF is -22.01. Epigenomics AG's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current EV-to-FCF is -22.01 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.87 is trading 866.7% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
EV-to-FCF: -22.01
GF Value™: €0.09 vs. price of €0.87 (866.7% above fair value)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
13GF Score
Get the complete analysis for FRA:ECX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
